A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Eligible age
18+ yrs
Accepts
All genders
Locations
37 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
Sponsor: Regeneron Pharmaceuticals
Where it's recruiting
Chandler · Gilbert · Tucson
Little Rock
Fullerton · Los Alamitos · Los Angeles · Orange …
Aurora · Englewood · Fort Collins
New Haven
Clermont · Jacksonville · Tamarac · Tampa
Athens · Columbus
Coeur d'Alene
Hinsdale · Park Ridge · Peoria
Fort Wayne
Westwood
Lexington
Source: ClinicalTrials.gov · NCT06246916 · last updated 2026-11-06